Targeted Drug Duo with Lighter Chemotherapy Delivers 97% Survival in Early-Stage Hodgkin Lymphoma
A phase 2 trial found that brentuximab vedotin and nivolumab added to limited chemotherapy produced a 92 percent complete response ...
A phase 2 trial found that brentuximab vedotin and nivolumab added to limited chemotherapy produced a 92 percent complete response ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine